Biologics & Biosimilars

Upadacitinib Promising for RA in Phase 3 Study

December 5, 2017 • By Michele B. Kaufman, PharmD, BCGP

Biosimilars Great Debate: To Switch or Not?

November 17, 2017 • By Susan Bernstein

Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD

October 22, 2017 • By Reuters Staff

Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

October 17, 2017 • By Mary Beth Nierengarten

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

October 17, 2017 • By Vanessa Caceres

Secukinumab Meets 5-Year Benchmark for Psoriasis

October 6, 2017 • By Michele B. Kaufman, PharmD, BCGP

Herpes Zoster & Tofacitinib

October 3, 2017 • By Arthritis & Rheumatology

Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

September 27, 2017 • By Michele B. Kaufman, PharmD, BCGP

CMS Implements Part B Modifiers for Biosimilars

September 20, 2017 • By From the College

FDA Approves First Biosimilar for the Treatment of Cancer

September 14, 2017 • By The U.S. Food and Drug Administration